Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice.

Pulmonary inflammation is a major contributor to morbidity in a variety of respiratory disorders, but treatment options are limited. Here we investigate the efficacy, safety and mechanism of action of low dose inhaled carbon monoxide (CO) using a mouse model of lipopolysaccharide (LPS)-induced pulmo...

Full description

Bibliographic Details
Main Authors: Michael R Wilson, Kieran P O'Dea, Anthony D Dorr, Hirotoshi Yamamoto, Michael E Goddard, Masao Takata
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-07-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2903490?pdf=render
_version_ 1828300930243624960
author Michael R Wilson
Kieran P O'Dea
Anthony D Dorr
Hirotoshi Yamamoto
Michael E Goddard
Masao Takata
author_facet Michael R Wilson
Kieran P O'Dea
Anthony D Dorr
Hirotoshi Yamamoto
Michael E Goddard
Masao Takata
author_sort Michael R Wilson
collection DOAJ
description Pulmonary inflammation is a major contributor to morbidity in a variety of respiratory disorders, but treatment options are limited. Here we investigate the efficacy, safety and mechanism of action of low dose inhaled carbon monoxide (CO) using a mouse model of lipopolysaccharide (LPS)-induced pulmonary inflammation.Mice were exposed to 0-500 ppm inhaled CO for periods of up to 24 hours prior to and following intratracheal instillation of 10 ng LPS. Animals were sacrificed and assessed for intraalveolar neutrophil influx and cytokine levels, flow cytometric determination of neutrophil number and activation in blood, lung and lavage fluid samples, or neutrophil mobilisation from bone marrow.When administered for 24 hours both before and after LPS, inhaled CO of 100 ppm or more reduced intraalveolar neutrophil infiltration by 40-50%, although doses above 100 ppm were associated with either high carboxyhemoglobin, weight loss or reduced physical activity. This anti-inflammatory effect of CO did not require pre-exposure before induction of injury. 100 ppm CO exposure attenuated neutrophil sequestration within the pulmonary vasculature as well as LPS-induced neutrophilia at 6 hours after LPS, likely due to abrogation of neutrophil mobilisation from bone marrow. In contrast to such apparently beneficial effects, 100 ppm inhaled CO induced an increase in pulmonary barrier permeability as determined by lavage fluid protein content and translocation of labelled albumin from blood to the alveolar space.Overall, these data confirm some protective role for inhaled CO during pulmonary inflammation, although this required a dose that produced carboxyhemoglobin values close to potentially toxic levels for humans, and increased lung permeability.
first_indexed 2024-04-13T13:16:28Z
format Article
id doaj.art-b19a3f4f34034d779f6f8cbd8532b0f4
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-13T13:16:28Z
publishDate 2010-07-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-b19a3f4f34034d779f6f8cbd8532b0f42022-12-22T02:45:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-07-0157e1156510.1371/journal.pone.0011565Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice.Michael R WilsonKieran P O'DeaAnthony D DorrHirotoshi YamamotoMichael E GoddardMasao TakataPulmonary inflammation is a major contributor to morbidity in a variety of respiratory disorders, but treatment options are limited. Here we investigate the efficacy, safety and mechanism of action of low dose inhaled carbon monoxide (CO) using a mouse model of lipopolysaccharide (LPS)-induced pulmonary inflammation.Mice were exposed to 0-500 ppm inhaled CO for periods of up to 24 hours prior to and following intratracheal instillation of 10 ng LPS. Animals were sacrificed and assessed for intraalveolar neutrophil influx and cytokine levels, flow cytometric determination of neutrophil number and activation in blood, lung and lavage fluid samples, or neutrophil mobilisation from bone marrow.When administered for 24 hours both before and after LPS, inhaled CO of 100 ppm or more reduced intraalveolar neutrophil infiltration by 40-50%, although doses above 100 ppm were associated with either high carboxyhemoglobin, weight loss or reduced physical activity. This anti-inflammatory effect of CO did not require pre-exposure before induction of injury. 100 ppm CO exposure attenuated neutrophil sequestration within the pulmonary vasculature as well as LPS-induced neutrophilia at 6 hours after LPS, likely due to abrogation of neutrophil mobilisation from bone marrow. In contrast to such apparently beneficial effects, 100 ppm inhaled CO induced an increase in pulmonary barrier permeability as determined by lavage fluid protein content and translocation of labelled albumin from blood to the alveolar space.Overall, these data confirm some protective role for inhaled CO during pulmonary inflammation, although this required a dose that produced carboxyhemoglobin values close to potentially toxic levels for humans, and increased lung permeability.http://europepmc.org/articles/PMC2903490?pdf=render
spellingShingle Michael R Wilson
Kieran P O'Dea
Anthony D Dorr
Hirotoshi Yamamoto
Michael E Goddard
Masao Takata
Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice.
PLoS ONE
title Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice.
title_full Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice.
title_fullStr Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice.
title_full_unstemmed Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice.
title_short Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice.
title_sort efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice
url http://europepmc.org/articles/PMC2903490?pdf=render
work_keys_str_mv AT michaelrwilson efficacyandsafetyofinhaledcarbonmonoxideduringpulmonaryinflammationinmice
AT kieranpodea efficacyandsafetyofinhaledcarbonmonoxideduringpulmonaryinflammationinmice
AT anthonyddorr efficacyandsafetyofinhaledcarbonmonoxideduringpulmonaryinflammationinmice
AT hirotoshiyamamoto efficacyandsafetyofinhaledcarbonmonoxideduringpulmonaryinflammationinmice
AT michaelegoddard efficacyandsafetyofinhaledcarbonmonoxideduringpulmonaryinflammationinmice
AT masaotakata efficacyandsafetyofinhaledcarbonmonoxideduringpulmonaryinflammationinmice